Skip to main content

Table 2 Drug treatments administered to patients at baseline and at the end of the study period

From: Clinical advantage and tolerability of ibandronate in hemodialysis patients: a retrospective study

  Baseline End of study
Anti-hypertensive agents
 Angiotensin receptor blocker 5 5
 Calcium channel blocker 6 6
 Alpha adrenergic blocker 2 2
 Beta blockers 2 2
HMG-CoA reductase inhibitors 0 0
Cinacalcet, n 2 2
Oral vitamin D 3 3
Intravenous vitamin D 8 8
Calcium polystyrene sulfonate 1 1
  1. Values represent number of medicines, n
  2. HMG-CoA hydroxymethylglutaryl-coenzyme A